Cited by 1,509Acute Myocardial Infarction ResearchCardiac Health and Mental HealthCardiac Ischemia and Reperfusion

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Open access

Freemantle, N., Cleland, J., Young, P., Mason, J., Harrison, J.·1999·BMJ

DOI 10.1136/bmj.318.7200.1730PMC PMC31101

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVES: To assess the effectiveness of beta blockers in short term treatment for acute myocardial infarction and in longer term secondary prevention; to examine predictive factors that may influence outcome and therefore choice of drug; and to examine the clinical importance of the results in the light of current treatment. DESIGN: Systematic review of randomised controlled trials. SETTING: Randomised controlled trials. SUBJECTS: Patients with acute or past myocardial infarction. INTERVENTION: beta Blockers compared with control. MAIN OUTCOME MEASURES: All cause mortality and non-fatal reinfarction. RESULTS: Overall, 5477 of 54 234 patients (10.1%) randomised to beta blockers or control died. We identified a 23% reduction in the odds of death in long term trials (95% confidence interval 15% to 31%), but only a 4% reduction in the odds of death in short term trials (-8% to 15%). Meta regression in long term trials did not identify a significant reduction in effectiveness in drugs with cardioselectivity but did identify a near significant trend towards decreased benefit in drugs with intrinsic sympathomimetic activity. Most evidence is available for propranolol, timolol, and metoprolol. In long term trials, the number needed to treat for 2 years to avoid a death is 42, which compares favourably with other treatments for patients with acute or past myocardial infarction. CONCLUSIONS: beta Blockers are effective in long term secondary prevention after myocardial infarction, but they are underused in such cases and lead to avoidable mortality and morbidity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/bmj.318.7200.1730

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Untitled work
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
Comparison of Invasive and Conservative Strategies after Treatment with Intravenous Tissue Plasminogen Activator in Acute Myocardial Infarction
The TIMI Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198903093201002 · Cited by 1,024
Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction
Gottlieb, S. S., McCarter, R., & Vogel, R. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390801 · Cited by 966
The Effect of Diltiazem on Mortality and Reinfarction after Myocardial Infarction
The Multicenter Diltiazem Postinfarction Trial Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190701 · Cited by 828
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
(1994) · Europe PMC (PubMed Central) · Cited by 755
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 637

Show all 34 references

Research works printed but not linked: 3

Viskin S, Barron HV. -Blockers prevent cardiac death following myocar- dial infarction: so why are so many infarct survivors discharge without -blockers? Am J Cardiol 1996;78:821-2.
Spiegelhalter D, Thomas A, Best N, Gilks W. BUGS: Bayesian inference using Gibbs sampling, Version 0.50. Cambridge: Medical Research Council Biostatistics Unit, 1995.
Feely J, de Vane PJ, Maclean D. -Blockers and sympathomimetics. BMJ 1983;286:1043-7.

Sorted by citations

Items 601–700 of 1,000

The major impacts of James Black's drug discoveries on medicine and pharmacology
Walker, M. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.001 · Cited by 19
Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension
Lundy, A.-L. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3066 · Cited by 19
Effective universal health coverage and improved 1-year survival after acute myocardial infarction: the Chilean experience
Carolina Nazzal, N., Frenz, P., Alonso, F. T., & Lanas, F. T. (2015) · Health Policy and Planning · doi:10.1093/heapol/czv120 · Cited by 19
Morphological and biomechanical aspects of vulnerable coronary plaque.
Finet, G., Jacques Ohayon, A., Rioufol, G., Floc’h, S. L., Tracqui, P., Dubreuil, O., & Tabib, A. (2007) · PubMed · Cited by 19
Managing Hypertension in the elderly: What’s new?
Aronow, W. S. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100001 · Cited by 31
Effect of Heart Rate on 1‐Year Outcome for Patients With Acute Ischemic Stroke
Lee, K., Kim, B. J., Han, M., Kim, J., Choi, K., Shin, D., Cha, J., Kim, D., Kim, D., Ryu, W., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025861 · Cited by 20
“The efficacy of β - blockers (antihypertensive agents that lower heart rate) was proven by clinical trials in patients with acute myocardial infarction for prevention of re-infarction and mortality, 26– 28 and their use is currently recommended.”
Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
Fox, D. J., Kibiro, M., Eichhöfer, J., & Curzen, N. P. (2005) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.023861 · Cited by 19
Ivabradine: Beyond heart rate control
Riccioni, G., Vitulano, N., & D’Orazio, N. (2009) · Advances in Therapy · doi:10.1007/s12325-008-0130-y · Cited by 18
Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm
FITCHETT, D. H., Borgundvaag, B., Cantor, W. J., Cohen, E. A., Dhingra, S., Fremes, S. E., Gupta, M., Heffernan, M., Kertland, H. R., Husain, M., et al. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70935-7 · Cited by 19
European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001).
Gandjour, A., Kleinschmit, F., & Lauterbach, K. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3080 · Cited by 21
A cardiologist view of vascular disease in diabetes
Lockhart, C., Hamilton, P., McVeigh, K., & McVeigh, G. E. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00727.x · Cited by 19
Tratamiento médico de la insuficiencia cardíaca basado en la evidencia
Agustí, A., Durán, M., Cumplido, D. R., Diogène, E., Arnau, J. M., Rodríguez, J. C., Basilio, E. G., & Lorite, N. M. (2001) · Revista Española de Cardiología · doi:10.1016/s0300-8932(01)76387-7 · Cited by 19
A cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease
Fox, K. F., Nuttall, M., Wood, D. A., Wright, M., Arora, B., Dawson, E., Devane, P., Stock, K., Sutcliffe, S. J., & Brown, K. (2001) · Heart · doi:10.1136/heart.85.5.533 · Cited by 20
Short-term/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction: a multicenter retrospective cohort study
Wen, X., Luo, R., Liu, J., Duan, Q., Qin, S., Xiao, J., & Zhang, D. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02631-8 · Cited by 18
Optimal Medical Therapy for Heart Failure
Bukharovich, I. F., & Kukin, M. L. (2006) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2005.11.002 · Cited by 18
Effect of Exposure to Evidence‐Based Pharmacotherapy on Outcomes After Acute Myocardial Infarction in Older Adults
Zuckerman, I. H., Yin, X., Rattinger, G. B., Gottlieb, S. S., Simoni‐Wastila, L., Pierce, S. A., HUANG, T.-Y. J., Shenolikar, R. A., & Stuart, B. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04165.x · Cited by 18
Secondary Preventive Effects of a Calcium Antagonist for Ischemic Heart Attack - Randomized Parallel Comparison With .BETA.-Blockers -
Nakagomi, A., Kodani, E., Takano, H., Uchida, T., Sato, N., Ibuki, C., Kusama, Y., Seino, Y., Munakata, K., Mizuno, K., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1078 · Cited by 18
Remodelling after an Infarct: Crosstalk between Life and Death
Ferrari, R., Malagù, M., Biscaglia, S., Fucili, A., & Rizzo, P. (2016) · Cardiology · doi:10.1159/000445882 · Cited by 18
Medications adherence post‐primary percutaneous coronary intervention in acute myocardial infarction: A population‐based cohort study
Rahhal, A. A. A., Mahfouz, A., Khir, F., Okleh, N., Aljundi, A. H., Alkhalaila, O., Hamid, Y., Al‐Amri, M., Al‐Yafei, S. A., Suwaidi, J. M. S. A., et al. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13348 · Cited by 19
Cardiovascular Disorders
Hamilton, D. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-68164-1_16 · Cited by 18
Reinforcing a Continuum of Care: In-Hospital Initiation of Long-Term Secondary Prevention Following Acute Coronary Syndromes
Rockson, S. G., deGoma, E. M., & Fonarow, G. C. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6043-1 · Cited by 17
The effects of heart rate on myocardial velocity and atrio-ventricular displacement during exercise with and without beta-blockade: a tissue Doppler echocardiographic study
Quintana, M., Gustafsson, T. P., Sundblad, P., & LANGANGER, J. (2004) · European Journal of Echocardiography · doi:10.1016/j.euje.2004.07.008 · Cited by 18
Renal and cardiovascular considerations for the nonpharmacological and pharmacological therapies of obesity-hypertension
Zhang, R., Thakur, V., Morse, S., & Reisin, E. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001496 · Cited by 18
The Role of Oral Antiplatelet Agents in Atherothrombotic Disease
Ferguson, J. J. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606030-00002 · Cited by 18
Coronary heart disease
Lovegrove, J. A., & Jackson, K. G. (2000) · Elsevier eBooks · doi:10.1533/9781855736436.2.97 · Cited by 18
Role of Intravenous β-Blockers in the Treatment of ST-Elevation Myocardial Infarction
Bates, E. (2007) · Circulation · doi:10.1161/circulationaha.107.707968 · Cited by 18
Atherosclerosis knowledge – diagnosis and management in primary care
Charasson, M., Mahé, G., Brun, C. L., Jaquinandi, V., Rossignol, E., Faucheur, A. L., & Omarjee, L. (2018) · VASA · doi:10.1024/0301-1526/a000727 · Cited by 17
Clinical Outcomes of Calcium-Channel Blocker vs Beta-Blocker
Kim, M. H., Yuan, S. L., Lee, K. M., Jin, X., Song, Z. Y., Cho, Y., Lee, M. S., Kim, J. H., & Jeong, M. H. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.02.006 · Cited by 17
“A meta-analysis that mostly included trials demonstrated that long-term BB therapy for more than 6 months was associated with a reduction in mortality.(19) However, those studies were conducted in the prereperfusion era.”
Background
Prescribing patterns of antihypertensive medications: A systematic review of literature between 2010 and 2020
Abdelkader, N. N., Awaisu, A., Elewa, H. F., & Hajj, M. S. E. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100315 · Cited by 17
Beta-Blocker Therapy After Myocardial Infarction
Miranda, P. C., Gašević, D., Trin, C., Stub, D. A., Zoungas, S., Kaye, D. M., Orman, Z., Eliakundu, A. L., & Talic, S. (2025) · JACC Advances · doi:10.1016/j.jacadv.2024.101582 · Cited by 23
Comparison of Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Discharged on Versus Not on Statin Therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial)
Larsen, A. I., Tomey, M. I., Mehran, R., Nilsen, D. W. T., Kirtane, A. J., Witzenbichler, B., Guagliumi, G., Brener, S. J., Généreux, P., Kornowski, R., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.401 · Cited by 17
Beta-1 vs. beta-2 adrenergic control of coronary blood flow during isometric handgrip exercise in humans
Maman, S. R., Pelaez, A. F. V., Ahmad, T. A., Miller, A. J., Gao, Z., Leuenberger, U. A., Proctor, D. N., & Muller, M. D. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00106.2017 · Cited by 17
Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer
González, R., Gockley, A. A., Melamed, A., Sugrue, R. P., Clark, R. M., Carmen, M. G. D., Growdon, W. B., Berkowitz, R. S., Horowitz, N. S., & Worley, M. J. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.03.012 · Cited by 17
Nanocomposites in 3D Bioprinting for Engineering Conductive and Stimuli‐Responsive Constructs Mimicking Electrically Sensitive Tissue
Züger, F., Marsano, A., Poggio, M., & Gullo, M. R. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100108 · Cited by 19
Role of drugs and devices in patients at risk of sudden cardiac death
Boriani, G., Diemberger, I., Valzania, C., Biffi, M., Martignani, C., Raschi, E., Mantovani, V., Ziacchi, M., Bertini, M., Ponti, F. D., et al. (2010) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00853.x · Cited by 17
Using Economic Analyses for Local Priority Setting
Heller, R. F., Gemmell, I., Wilson, E., Fordham, R. J., & Smith, R. (2006) · Applied Health Economics and Health Policy · doi:10.2165/00148365-200605010-00006 · Cited by 17
Prevention of ventricular fibrillation requires central β-adrenoceptor blockade in rabbits
Åblad, B., Bjurö, T., Björkman, J., & Edström, T. (2007) · Scandinavian Cardiovascular Journal · doi:10.1080/14017430701383748 · Cited by 17
Management and Outcomes of Renal Disease and Acute Myocardial Infarction
Santolucito, P. A., Tighe, D. A., McManus, D. D., Yarzebski, J., Lessard, D., Gore, J. M., & Goldberg, R. J. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.04.025 · Cited by 17
Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study
Lopez-Carmona, M. D., Bernal-Lopez, M., Mancera‐Romero, J., Jansen‐Chaparro, S., Portales-Fernandez, I., Baca-Osorio, A., Pérez-González, R., Tinahones, F. J., & Gómez‐Huelgas, R. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711418166 · Cited by 17
Effects of β‐blockers on all‐cause mortality in patients with type 2 diabetes and coronary heart disease
Tsujimoto, T., Sugiyama, T., & Kajio, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12878 · Cited by 17
Thymosin β4 promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium
Quan, Z., Wang, Q., Zhou, P., Wang, G., Tan, Y., & Wang, H. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2950 · Cited by 17
Ischemic heart disease in women and the role of hormone therapy
Raza, J. A., Reinhart, R. A., & Movahed, A. (2003) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.06.013 · Cited by 18
Beta-blockers and the treatment of hypertension: it is time to move on.
Wiysonge, C. S., Volmink, J. A., & Opie, L. H. (2007) · PubMed Central · Cited by 17
β-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Warmack, T. S., Estes, M., Heldenbrand, S. D., & Franks, A. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m381 · Cited by 17
Early Drug Therapy and In-Hospital Mortality following Acute Myocardial Infarction
Erné, P., Radovanović, D., Urban, P. M., Stauffer, J., Bertel, O., & Gutzwiller, F. F. (2003) · Heart Drug · doi:10.1159/000073838 · Cited by 17
Numbers Needed to Treat Derived from Meta‒Analyses: Pitfalls and Cautions
Ebrahim, S. B. J. (2001) · doi:10.1002/9780470693926.ch20 · Cited by 17
Effect of β-Blockers on Cardiac and Pulmonary Events and Death in Older Adults With Cardiovascular Disease and Chronic Obstructive Pulmonary Disease
Lee, D. S. H., Markwardt, S., McAvay, G., Gross, C. P., Goeres, L. M., Han, L., Peduzzi, P. N., Lin, H., Dodson, J. A., & Tinetti, M. E. (2014) · Medical Care · doi:10.1097/mlr.0000000000000035 · Cited by 16
Sex Differences in the Treatment and Outcome of Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Population-Based Study
Lin, C.-F., Shen, L., Hsiao, F., Gau, C., & Wu, F. L. (2013) · Journal of Women s Health · doi:10.1089/jwh.2013.4474 · Cited by 16
Understanding the Improvement in Disability-Free Life Expectancy in the U.S. Elderly Population
Chernew, M. E., Cutler, D., Ghosh, K., & Landrum, M. B. (2016) · doi:10.7208/9780226426709-007 · Cited by 16
The future: therapy of myocardial protection
Sanz‐Rosa, D., García‐Prieto, J., & Ibáñez, B. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06501.x · Cited by 16
Safety and tolerability during build-up phase of a rush venom immunotherapy
Bernkopf, K., Rönsch, H., Spornraft‐Ragaller, P., Neumeister, V., & Bauer, A. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.02.014 · Cited by 16
Glycyrrhizic Acid Reduces Heart Rate and Blood Pressure by a Dual Mechanism
Singh, K., Zaw, A. M., Sekar, R., Ahuja, P., Allam, A. A., Jamaan, A., & Chow, B. (2016) · Molecules · doi:10.3390/molecules21101291 · Cited by 16
β-Blockers in myocardial infarction and coronary artery disease with a preserved ejection fraction
Nambiar, L., & Meyer, M. (2018) · Coronary Artery Disease · doi:10.1097/mca.0000000000000610 · Cited by 16
Minimally invasive transtracheal cardiac plexus block for sympathetic neuromodulation
Assis, F., Yu, D. H., Zhou, X. J., Sidhu, S., Bapna, A., Engelman, Z. J., Misra, S. K., Okada, D. R., Chrispin, J., Berger, R. D., et al. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2018.07.037 · Cited by 16
Development and Validation of a Method for the Analysis of Bisoprolol and Atenolol in Human Bone
Fernández-López, L., Pellegrini, M., Rotolo, M. C., Maldonado, A. L., Romero, M. F., & Mancini, R. (2019) · Molecules · doi:10.3390/molecules24132400 · Cited by 16
Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008
Lobos, J. M., Royo‐Bordonada, M. Á., Brotons, C., Sala, L. A., Armario, P., Maiques, A., Mauricio, D., Sans, S., Villar, F., Lizcano, A. P. R., et al. (2009) · Revista Clínica Española · doi:10.1016/s0014-2565(09)71477-8 · Cited by 16
Mortality and Reinfarction among Patients Using Different Beta-Blockers for Secondary Prevention after a Myocardial Infarction
Andersen, S. S., Hansen, M. L., Gislason, G., Folke, F., Schramm, T. K., Fosbøl, E. L., Sørensen, R., Rasmussen, S., Abildstrom, S. Z., Madsen, M., et al. (2008) · Cardiology · doi:10.1159/000143389 · Cited by 16
RESPONSE study: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists
Jorstad, H. T., ALINGS, A. M. W., Liem, A. H., von Birgelen, C., Tijssen, J. G. P., de Vries, C. J., Lok, D. J. A., Kragten, J. A., & Peters, R. J. G. (2009) · Netherlands Heart Journal · doi:10.1007/bf03086277 · Cited by 16
Beta-Blocker Prescription Among Japanese Cardiologists and Its Effect on Various Outcomes
Kohro, T., Hayashi, D., Yamazaki, T., Nagai, R., & The JCAD Investigators (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0613 · Cited by 16
Impact of Coaching Patients on Coronary Risk Factors
Vale, M. J., Jelinek, M. V., & Best, J. D. (2005) · Disease Management & Health Outcomes · doi:10.2165/00115677-200513040-00002 · Cited by 16
“Despite available proven strategies to treat risk factors for Other drugs that have been clearly shown to reduce mortality CHD, current evidence illustrates disappointingly slow, and in after discharge from hospital include aspirin (acetylsalicylic many cases, limited implementation of these therapies in clinical acid…”
Background
ACE up the sleeve – are vascular patients medically optimized
Coveney, A. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s15484 · Cited by 15
β-Blockers as Antiarrhythmic Agents
Priori, S. G., Napolitano, C., & Cerrone, M. (2006) · Springer eBooks · doi:10.1007/3-540-29715-4_9 · Cited by 16
Use of local anesthesia in ear surgery: technique, modifications, advantages, and limitations over 30 years’ experience
El‐Begermy, M. A., El-Begermy, M. M., Rabie, A. N., Ezzat, A. E. M., & Sheesh, A. A. K. (2016) · The Egyptian Journal of Otolaryngology · doi:10.4103/1012-5574.186541 · Cited by 16
Update of ELITE-II, BEST, CHAMP, and IMPRESS Clinical Trials in Heart Failure
Witte, K. K., Thackray, S. D. R., Banerjee, T., Clark, A. L., & Cleland, J. G. F. (2000) · European Journal of Heart Failure · doi:10.1016/s1388-9842(00)00053-2 · Cited by 16
Self-citation
Benefits and harms of perioperative beta-blockade
Wetterslev, J., & Juul, A. B. (2006) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2005.10.006 · Cited by 16
Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus
Jørgensen, C. H., Gislason, G., Ahlehoff, O., Andersson, C., Torp-Pedersen, C. T., & Hansen, P. R. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-4 · Cited by 16
“study period but combination therapies appear to remain underused as compared to treatment guidelines [2,3,23].”
Background
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction
Mrdović, I., Savić, L., Peruničić, J., Ašanin, M., Lasica, R., Jelena, M. M., Matic, M., Vasiljević, Z., & Ostojić, M. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.03.049 · Cited by 16
Con: Beta-Blockers Are Indicated for All Adults at Increased Risk Undergoing Noncardiac Surgery
London, M. J. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000231830.13665.05 · Cited by 16
“enhanced long-term survival) (27) and their long-term”
Eurasian clinical guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
Барбараш, О. Л., Komarov, A. L., Панченко, Е. П., Староверов, И. И., Shakhnovich, R. M., & Yavelov, I. S. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-4-6-59 · Cited by 16
Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
Nogic, J., Mehta, O., Tong, D., Brown, A. J., & Layland, J. J. (2023) · Cardiology and Therapy · doi:10.1007/s40119-022-00298-y · Cited by 15
Colchicine for secondary prevention in patients with acute coronary syndrome: A systematic review and meta-analysis
Shaikh, S., Hamza, M., Neppala, S., Singh, S., Upreti, P., Umer, A. M., Manish, K. C., Pandya, K. K., Bahar, Y., Sattar, Y., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133045 · Cited by 16
Type of β-blocker use among patients with versus without diabetes after myocardial infarction
Arnold, S. V., Spertus, J. A., Lipska, K. J., Lanfear, D. E., Tang, F., Grodzinsky, A., McGuire, D. K., Gore, M. O., Goyal, A., Maddox, T. M., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.04.018 · Cited by 15
Relation of β-Blocker Use With Frequency of Hospitalization for Heart Failure in Patients With Left Ventricular Diastolic Dysfunction (from the Heart and Soul Study)
Smith, D. T., Farzaneh‐Far, R., Ali, S., Na, B., Whooley, M. A., & Schiller, N. B. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.08.677 · Cited by 15
Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial
Mariani, J. A., Rosende, A., Abreu, M. D., Monte, G. G. V., D’Imperio, H., Antonietti, L., Lemonnier, G., Bonis, A. D., & Tajer, C. D. (2020) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944720912071 · Cited by 15
Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
Lee, P. H., Park, G., Han, S., Kim, Y., Lee, J., Roh, J., Lee, J., Kim, Y., & Lee, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-79214-0 · Cited by 15
Translation of clinical trials into clinical practice
Julian, D. G. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01282.x · Cited by 15
Kidney Function and Population-Based Outcomes of Initiating Oral Atenolol Versus Metoprolol Tartrate in Older Adults
Fleet, J. L., Weir, M. A., McArthur, E., Ozair, S., Devereaux, P. J., Roberts, M. A., Jain, A. K., & Garg, A. X. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.06.009 · Cited by 15
Acute myocardial infarction — Historical notes
Teixeira, R. P., Gonçalves, L. M. M., & Gersh, B. J. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.066 · Cited by 15
Beta-blockers in heart failure. 2. Mode of action
Nuttall, S. L., Langford, N. J., & Kendall, M. J. (2001) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2001.00316.x · Cited by 15
Inhaled glucocorticoids in COPD
Sin, D. D., Man, S. F. P., Tu, J. V., Pride, N. B., Vestbo, J., Soriano, J. B., & Kiri, V. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.168.1.950 · Cited by 15
Coronary Artery Disease Prevention
Sherazi, S., & Block, R. (2009) · Springer eBooks · doi:10.1007/978-1-84882-185-9_2 · Cited by 15
The Population Risks of Dietary Salt Excess Are Exaggerated
Mente, A., O'Donnell, M. J., & Yusuf, S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.003 · Cited by 14
The Effects of Clinical Pharmacist Education on Lifestyle Modifications of Postmyocardial Infarction Patients in South India: A Prospective Interventional Study
Sundararajan, S., Sathanantham, S. T., & Palani, S. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100577 · Cited by 14
Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery.
Philip, F., Blackstone, E. H., & Kapadia, S. R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-3652.2015.02.01 · Cited by 14
“org entered into 82 randomized trials found that short-term beta blockade immediately after an acute MI was unlikely to be of major benefit unless treatment was discontinued long-term (22).”
Background
Outcomes of after-hours versus regular working hours primary percutaneous coronary intervention for acute myocardial infarction
Graham, M. M., Ghali, W. A., Southern, D. A., Traboulsi, M., Knudtson, M. L., & for the APPROACH Investigators (2011) · BMJ Quality & Safety · doi:10.1136/bmjqs.2010.041137 · Cited by 14
Rotigaptide Infusion for the First 7 Days After Myocardial Infarction–Reperfusion Reduced Late Complexity of Myocardial Architecture of the Healing Border‐Zone and Arrhythmia Inducibility
Chowdhury, R. A., Debney, M. T., Protti, A., Handa, B. S., Patel, K. H. K., Lyon, A. R., Shah, A. M., Ng, F. S., & Peters, N. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020006 · Cited by 14
Is cardiac rehabilitation still relevant in the new millennium?
Dobson, L. E., Lewin, R., Doherty, P., Batin, P. D., Megarry, S., & Gale, C. P. (2011) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32834d4571 · Cited by 13
Secondary Prevention Medication After Myocardial Infarction: Persistence in Elderly People over the Course of 1 Year
Al-Khadra, S., Meisinger, C., Amann, U., Holle, R., Kuch, B., Seidl, H., & Kirchberger, I. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0189-x · Cited by 15
“The continuous use of medication has been shown to strongly reduce risk of all-cause mortality [4–6], hospital readmission and healthcare costs [6–8].”
Background
The role of β-blockers in the management of hypertension: An Asian perspective
Tomlinson, B., Dalal, J. J., Huang, J., Low, L. P., Park, C. G., Rahman, A., Reyes, E. B., Soenarta, A. A., Heagerty, A. M., & Folláth, F. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.562884 · Cited by 14
A new horizon in primary prevention of cardiovascular disease, can we prevent heart attack by "heart polypill"?
Rastegarpanah, M., Malekzadeh, F., Thomas, G. N., Mohagheghi, A., Cheng, K. K., & Marshall, T. P. (2008) · PubMed · Cited by 14
Assessment and management of resistant hypertension
Padwal, R. S., Rabkin, S. W., & Khan, N. A. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.130764 · Cited by 14
Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction
González-Cambeiro, M. C., López-López, A., Abu‐Assi, E., Raposeiras‐Roubín, S., Peña, C., García‐Acuña, J. M., & González-Juanatey, R. (2016) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2016.07.003 · Cited by 15
Beta‐Blocker Use in U.S. Nursing Home Residents After Myocardial Infarction: A National Study
Zullo, A. R., Lee, Y., Daiello, L. A., Mor, V., Boscardin, W. J., Dore, D. D., Miao, Y., Fung, K. Z., Komaiko, K. D. R., & Steinman, M. A. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14671 · Cited by 14
Meta-Analysis Comparing Metoprolol and Carvedilol on Mortality Benefits in Patients With Acute Myocardial Infarction
Li, J., Chen, Z., Gao, X., Zhang, H., Xiong, W., Ju, J., & Xu, H. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.036 · Cited by 14
Current use of beta-blockers in patients with coronary artery disease
Andreasen, C., & Andersson, C. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.014 · Cited by 14
Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure and Systolic Dysfunction
Thattassery, E., & Gheorghiade, M. (2004) · Heart Failure Reviews · doi:10.1023/b:hrev.0000046365.53467.f4 · Cited by 14
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease
Dorval, J., Anderson, T. J., Buithieu, J., Chan, S., Hutchison, S., Huynh, T. T., Jobin, J., Lonn, E., Poirier, P., Title, L. M., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.012 · Cited by 14
The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross‐sectional study in general practice
Connolly, P., Cupples, M., Cuene‐Grandidier, H., Johnston, D., & Passmore, P. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.709 · Cited by 14
Beta-Blockers in Asymptomatic Coronary Artery Disease
Steg, P. G., & de Silva, R. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.043 · Cited by 14
The Art of Prescribing β-Blockers After Myocardial Infarction
Desta, L., Raposeiras‐Roubín, S., & Ibáñez, B. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.010720 · Cited by 14

Authors: Freemantle, N., Cleland, J., Young, P., Mason, J., & Harrison, J.
Affiliations: University of York (GB)
University of Hull (GB)
Corresponding author: Freemantle, N.
ORCID: Freemantle, N.
Cleland, J.
Mason, J.
Venue: BMJ
Publisher: BMJ
Published: 1999-06-26
Volume: 318
Issue: 7200
Pages: 1730-1737
ISSN: 0007-1447 (ISSN-L)
0959-8138
1468-5833
DOI: 10.1136/bmj.318.7200.1730
PMC: PMC31101
OpenAlex: W2070568974
Cited by: 1,509
References: 34
Citations by year: 2026: 27 · 2025: 43 · 2024: 38 · 2023: 30 · 2022: 42 · 2021: 36 · 2020: 49 · 2019: 47 · 2018: 53 · 2017: 57 · 2016: 58 · 2015: 48 · 2014: 67 · 2013: 74 · 2012: 83
FWCI: 7.55
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: BMJ (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Keywords: beta-blockers, myocardial infarction, secondary prevention, all-cause mortality, reinfarction, cardioselectivity, intrinsic sympathomimetic activity, propranolol, timolol, metoprolol, number needed to treat, predictors of treatment response
MeSH terms: Adrenergic beta-Antagonists, Humans, Myocardial Infarction, Regression Analysis, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

beta Blockade after myocardial infarction: systematic review and meta regression analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks